Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry
Journal of Clinical Lipidology · 2023
DOI: 10.1016/j.jacl.2023.09.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2023. Verfasst von Meral Kayıkcioglu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (Dr Kayıkcioglu), Ege University Faculty of Medicine, İzmir, Turkey. Electronic address: meral.kayikcioglu@gmail.com. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II, Cardiology, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is a common inherited disease, leading to premature atherosclerotic cardiovascular disease (ASCVD) due to elevated low-density lipoprotein cholesterol (LDL-C) levels. Achieving LDL-C goals is extremely important for preventing the complications of this fatal disease. We evaluated the management of FH patients with ASCVD in cardiology practice. METHODS: We analyzed patients with ASCVD from the nationwide EPHESUS registry, which was conducted in 40 cardiology outpatient clinics, and compared those with and without FH. RESULTS: Of the 1482 consecutively enrolled patients with ASCVD, 618 (41.7%) had FH, among which 455 were categorized as 'Possible FH' and 163 as 'Probable or Definite FH'. Proposed LDL-C goals were not attained in more than 90% of the patients with FH. The proportion of those on statin therapy was 77% for possible and 91% for probable or definite FH, whereas 34.2 % and 59.4% were in use of high-intensity statins, respectively. None of the patients were on PCSK-9 inhibitors, and only 2 used ezetimibe. Adverse media coverage was the most common cause of statin discontinuation (32.5% in 'possible FH' and 45.7% in 'probable/definite FH'). The negative impact of media in the decision to stop lipid lowering therapy (LLT) was increasing with education level. CONCLUSIONS: In real life most of the FH patients with ASCVD are undertreated in cardiology practice regarding statin dosing and combined LLT. Drug discontinuation rates are notably high and are mostly media-related, and side effects very rarely cause cessation of LLT. Urgent measures are needed to increase the awareness of FH among healthcare providers and patients and to develop improved treatment strategies aimed at preventing the complications of FH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology (Dr Kayıkcioglu), Ege University Faculty of Medicine, İzmir, Turkey. Electronic address: meral.kayikcioglu@gmail.com.
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey.
- Department of Cardiology (Dr Mert), Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey.
- Department of Cardiology (Dr Özdemir), Manisa City Hospital, Manisa, Turkey.
- Department of Cardiology (Dr Rencüzoğulları), Kafkas University Faculty of Medicine, Kars, Turkey.
- Department of Cardiology (Dr Karadeniz), Karamanoglu Mehmetbey University Faculty of Medicine, Karaman, Turkey.
Zitieren
APA
Kayıkcioglu, M., Başaran, Ö., Doğan, V., Mert, K. U., Mert, G. Ö., Özdemir, İ. H., Rencüzoğulları, İ., Karadeniz, F. Ö., Tekinalp, M., Aşkın, L., Demirelli, S., Gencer, E., Bekar, L., Aktaş, M., Resulzade, M. M., Kalçık, M., Aksan, G., Cinier, G., Akay, K. H., …, & Biteker, M. (2023). Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2023.09.013
Vancouver
Kayıkcioglu M, Başaran Ö, Doğan V, Mert KU, Mert GÖ, Özdemir İH, et al. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. Journal of Clinical Lipidology. 2023. doi:10.1016/j.jacl.2023.09.013
BibTeX
@article{Kaykcioglu2023,
author = {Kayıkcioglu, Meral and Başaran, Özcan and Doğan, Volkan and Mert, Kadir Uğur and Mert, Gurbet Özge and Özdemir, İbrahim Halil and Rencüzoğulları, İbrahim and Karadeniz, Fatma Özpamuk and Tekinalp, Mehmet and Aşkın, Lütfü and Demirelli, Selami and Gencer, Erkan and Bekar, Lütfü and Aktaş, Müjdat and Resulzade, Mübariz Murat and Kalçık, Macit and Aksan, Gökhan and Cinier, Göksel and Akay, Kadriye Halli and Pekel, Nihat and Utku Şenol and Demir, Vahit and İnci, Sinan and Derviş, Emir and Özlek, Bülent and Özlek, Eda and Çelik, Oğuzhan and Çil, Cem and Biteker, Murat},
title = {Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry},
journal = {Journal of Clinical Lipidology},
year = {2023},
doi = {10.1016/j.jacl.2023.09.013}
}
EUVIMED